RU2014844C1 - Method for treating viral diarrhea - Google Patents
Method for treating viral diarrhea Download PDFInfo
- Publication number
- RU2014844C1 RU2014844C1 SU5040957A RU2014844C1 RU 2014844 C1 RU2014844 C1 RU 2014844C1 SU 5040957 A SU5040957 A SU 5040957A RU 2014844 C1 RU2014844 C1 RU 2014844C1
- Authority
- RU
- Russia
- Prior art keywords
- age
- day
- children
- months
- years
- Prior art date
Links
Abstract
Description
Изобретение относится к медицине, в частности к лечению инфекционных заболеваний. The invention relates to medicine, in particular to the treatment of infectious diseases.
Известны способы комплексного лечения вирусных диарей с применением оральной регидратации, биопрепаратов, имодиума. Однако, обладая патогенетической направленностью, они не включают в себя специфического противовирусного воздействия на возбудитель заболевания. Known methods for the complex treatment of viral diarrhea using oral rehydration, biological products, imodium. However, having a pathogenetic orientation, they do not include a specific antiviral effect on the causative agent of the disease.
Препараты интерферона применялись в медицинской практике как противовирусные, а в последние годы и иммуномодулирующие средства в лечении вирусных и бактериальных инфекций. Interferon preparations have been used in medical practice as antiviral and, in recent years, immunomodulating agents in the treatment of viral and bacterial infections.
Более близким способом в комплексной терапии диарей у детей является использование человеческого лейкоцитарного интерферона путем ректального его введения. A closer way in the complex treatment of diarrhea in children is the use of human leukocyte interferon by rectal administration.
При этом интерферон использовался в лечении не вирусных, а бактериальных кишечных инфекций в расчете на его иммуномодулирующее действие. At the same time, interferon was used in the treatment of bacterial intestinal infections rather than viral infections, based on its immunomodulating effect.
В качестве прототипа заявляемого способа принят способ лечения острых вирусных диарей с применением антидиарейного препарата - лоперамида, известного в нашей стране под названием имодиум. Препарат уменьшает объем и содержание воды в испражнениях, увеличивает резорбцию жидкости. Однако он не оказывает непосредственного воздействия на возбудителя диареи. Кроме того, возможность развития побочных реакций в виде тошноты, рвоты, нарастания интоксикации, пареза кишечника требуют сокращения доз, кратности и сроков введения препарата. As a prototype of the proposed method, a method for the treatment of acute viral diarrhea with the use of an antidiarrheal drug - loperamide, known in our country as imodium, has been adopted. The drug reduces the volume and content of water in the feces, increases the resorption of the liquid. However, it does not directly affect the causative agent of diarrhea. In addition, the possibility of developing adverse reactions in the form of nausea, vomiting, increased intoxication, paresis of the intestine require a reduction in doses, frequency and timing of the drug.
Целью изобретения является сокращение сроков лечения с одновременным снижением числа побочных реакций. The aim of the invention is to reduce the duration of treatment while reducing the number of adverse reactions.
Указанная цель достигается ректальным введением хорошо очищенного, высококонцентрированного генно-инженерного интерферона - реаферона (реальдирона) по 20-100 тыс. МЕ/кг массы тела 2 раза в сутки, в том числе детям до 6 мес. по 100 тыс. МЕ/кг двукратно, детям от 6 мес. до года по 50 тыс. МЕ/кг, двукратно, детям от года до 12 лет по 20 тыс. МЕ/кг двукратно и больным старше 12 лет по 1 млн МЕ два раза в сутки. This goal is achieved by rectal administration of a well-purified, highly concentrated genetic engineering interferon - reaferon (realdiron) of 20-100 thousand IU / kg body weight 2 times a day, including children up to 6 months. 100 thousand IU / kg twice, for children from 6 months. up to a year of 50 thousand IU / kg, twice, for children from a year to 12 years of 20 thousand IU / kg twice and for patients older than 12 years of 1 million IU twice a day.
Существенность отличий предлагаемого способа заключается в использовании перспективных, очищенных, высококонцентрированных генно-инженерных интерферонов (реаферон, реальдирон), обладающих выраженной противовирусной активностью, и, следовательно, действующих непосредственно на возбудителя заболевания. Ректальное введение реаферона наиболее приемлемо в детской практике, более удобно и безвредно по сравнению с внутривенным или внутримышечным его введением. The significance of the differences of the proposed method consists in the use of promising, purified, highly concentrated genetically engineered interferons (reaferon, realdirone) with pronounced antiviral activity, and, therefore, acting directly on the causative agent of the disease. Rectal administration of reaferon is most acceptable in pediatric practice, more convenient and harmless in comparison with its intravenous or intramuscular administration.
Конкретный пример выполнения способа. A specific example of the method.
Ребенок О.С., 3,5 мес. история болезни N 636, 1991 г. С 30.01.91 г. находился в грудном отделении по поводу ОРВИ, левостороннего катарального отита, анемии II степени, рахита II степени, перинатальной энцефалопатии. Baby O.S., 3.5 months. medical history N 636, 1991. From 30.01.91, he was in the thoracic department for acute respiratory viral infections, left-sided catarrhal otitis media, anemia of the II degree, rickets of the II degree, perinatal encephalopathy.
Получал оксациллин внутримышечно, бифидумбактерин, симптоматическое лечение, на фоне чего отмечено улучшение в состоянии. He received intramuscular oxacillin, bifidumbacterin, symptomatic treatment, against which an improvement in condition was noted.
С четвертого дня госпитализации внезапно регистрируется ухудшение состояния - подъем температуры до 38оС, повторная рвота, увеличение кратности стула до 15 раз в сутки, в связи с чем больной переведен в диагностическое кишечное отделение. При осмотре беспокоен, быстро утомляется, повторяется рвота, гемодинамические нарушения в виде бледности и мраморности кожных покровов, цианоз при крике, приглушенность сердечных тонов. Кожа и слизистые суховаты. Живот вздут, урчание по ходу тонкого кишечника. Потеря массы тела 650,0 г. Стул бескаловый, водянистый, салатового цвета до 15 раз в сутки.On the fourth day of hospitalization suddenly registered deterioration - the temperature rise to 38 ° C, repeated vomiting, increasing multiplicity of the chair to 15 times a day, and therefore the patient is transferred to the diagnostic intestinal compartment. On examination, he is anxious, quickly tired, vomiting is repeated, hemodynamic disturbances in the form of pallor and marbling of the skin, cyanosis during screaming, muffled heart sounds. The skin and mucous membranes are rather dry. The abdomen is swollen, rumbling along the small intestine. The loss of body weight is 650.0 g. The stool is calcite-free, watery, light green in color up to 15 times a day.
Предположительный диагноз вирусной диареи подтвержден обнаружением ротавируса методами электронной микроскопии и иммуноферментного анализа. A presumptive diagnosis of viral diarrhea is confirmed by the detection of rotavirus by electron microscopy and enzyme-linked immunosorbent assay.
Антибактериальная терапия снята. Ректально назначен реальдирон в дозе 100 тыс. МЕ/кг (500 тыс. МЕ) два раза в сутки. Antibacterial therapy is removed. Rectalone was prescribed rectally at a dose of 100 thousand IU / kg (500 thousand IU) twice a day.
Улучшение состояния отмечено уже со второго дня назначения препарата. Исчезли явления токсикоза, значительно уменьшились проявления интоксикации. Улучшилось общее состояние. Стул стал каловым, желтым. Кратность его сократилась до 5 раз в сутки. К третьему дню от начала лечения купировались симптомы интоксикации, нормализовалась температура. Полная нормализация стула отмечена к 4-му дню. Имела место и вирусологическая санация - повторного обнаружения ротавирусов в фекалиях больного не отмечено. Выписан домой в удовлетворительном состоянии. Improvement was noted already from the second day of the drug. The effects of toxicosis disappeared, the manifestations of intoxication significantly decreased. The general condition has improved. The chair turned fecal, yellow. Its multiplicity was reduced to 5 times a day. By the third day from the start of treatment, symptoms of intoxication stopped, the temperature returned to normal. Complete stool normalization was noted by the 4th day. Virological sanitation also took place - there was no re-detection of rotaviruses in the feces of the patient. Discharged home in satisfactory condition.
Преимуществом предлагаемого способа является сокращение сроков лечения, более быстрая клиническая и вирусологическая санации при простоте и удобстве выполнения, а также отсутствие побочных реакций, регистрируемых при лечении вирусных диарей антидиарейными препаратами. The advantage of the proposed method is the reduction of treatment time, faster clinical and virological sanitation with simplicity and ease of implementation, as well as the absence of adverse reactions recorded in the treatment of viral diarrhea with antidiarrheal drugs.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SU5040957 RU2014844C1 (en) | 1992-05-06 | 1992-05-06 | Method for treating viral diarrhea |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SU5040957 RU2014844C1 (en) | 1992-05-06 | 1992-05-06 | Method for treating viral diarrhea |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2014844C1 true RU2014844C1 (en) | 1994-06-30 |
Family
ID=21603621
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SU5040957 RU2014844C1 (en) | 1992-05-06 | 1992-05-06 | Method for treating viral diarrhea |
Country Status (1)
Country | Link |
---|---|
RU (1) | RU2014844C1 (en) |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7006871B1 (en) | 1997-07-16 | 2006-02-28 | Metacure N.V. | Blood glucose level control |
US7120497B2 (en) | 1997-07-16 | 2006-10-10 | Metacure Nv | Smooth muscle controller |
US7840262B2 (en) | 2003-03-10 | 2010-11-23 | Impulse Dynamics Nv | Apparatus and method for delivering electrical signals to modify gene expression in cardiac tissue |
US8019421B2 (en) | 1999-03-05 | 2011-09-13 | Metacure Limited | Blood glucose level control |
US8244371B2 (en) | 2005-03-18 | 2012-08-14 | Metacure Limited | Pancreas lead |
US8260416B2 (en) | 1996-01-08 | 2012-09-04 | Impulse Dynamics, N.V. | Electrical muscle controller |
US8321013B2 (en) | 1996-01-08 | 2012-11-27 | Impulse Dynamics, N.V. | Electrical muscle controller and pacing with hemodynamic enhancement |
US8346363B2 (en) | 1999-03-05 | 2013-01-01 | Metacure Limited | Blood glucose level control |
US8352031B2 (en) | 2004-03-10 | 2013-01-08 | Impulse Dynamics Nv | Protein activity modification |
US8548583B2 (en) | 2004-03-10 | 2013-10-01 | Impulse Dynamics Nv | Protein activity modification |
US8655444B2 (en) | 1996-01-08 | 2014-02-18 | Impulse Dynamics, N.V. | Electrical muscle controller |
US8666495B2 (en) | 1999-03-05 | 2014-03-04 | Metacure Limited | Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar |
US8700161B2 (en) | 1999-03-05 | 2014-04-15 | Metacure Limited | Blood glucose level control |
US8792985B2 (en) | 2003-07-21 | 2014-07-29 | Metacure Limited | Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar |
US8825152B2 (en) | 1996-01-08 | 2014-09-02 | Impulse Dynamics, N.V. | Modulation of intracellular calcium concentration using non-excitatory electrical signals applied to the tissue |
US8934975B2 (en) | 2010-02-01 | 2015-01-13 | Metacure Limited | Gastrointestinal electrical therapy |
US9101765B2 (en) | 1999-03-05 | 2015-08-11 | Metacure Limited | Non-immediate effects of therapy |
US9289618B1 (en) | 1996-01-08 | 2016-03-22 | Impulse Dynamics Nv | Electrical muscle controller |
US9713723B2 (en) | 1996-01-11 | 2017-07-25 | Impulse Dynamics Nv | Signal delivery through the right ventricular septum |
US9931503B2 (en) | 2003-03-10 | 2018-04-03 | Impulse Dynamics Nv | Protein activity modification |
US11439815B2 (en) | 2003-03-10 | 2022-09-13 | Impulse Dynamics Nv | Protein activity modification |
US11779768B2 (en) | 2004-03-10 | 2023-10-10 | Impulse Dynamics Nv | Protein activity modification |
-
1992
- 1992-05-06 RU SU5040957 patent/RU2014844C1/en active
Non-Patent Citations (1)
Title |
---|
Крамаров С. и др. - Вопросы охраны материнства и детства. - 1989, N 10, с.22-24. * |
Cited By (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8655444B2 (en) | 1996-01-08 | 2014-02-18 | Impulse Dynamics, N.V. | Electrical muscle controller |
US9186514B2 (en) | 1996-01-08 | 2015-11-17 | Impulse Dynamics Nv | Electrical muscle controller |
US9289618B1 (en) | 1996-01-08 | 2016-03-22 | Impulse Dynamics Nv | Electrical muscle controller |
US8958872B2 (en) | 1996-01-08 | 2015-02-17 | Impulse Dynamics, N.V. | Electrical muscle controller |
US8825152B2 (en) | 1996-01-08 | 2014-09-02 | Impulse Dynamics, N.V. | Modulation of intracellular calcium concentration using non-excitatory electrical signals applied to the tissue |
US8321013B2 (en) | 1996-01-08 | 2012-11-27 | Impulse Dynamics, N.V. | Electrical muscle controller and pacing with hemodynamic enhancement |
US8311629B2 (en) | 1996-01-08 | 2012-11-13 | Impulse Dynamics, N.V. | Electrical muscle controller |
US8306616B2 (en) | 1996-01-08 | 2012-11-06 | Impulse Dynamics, N.V. | Electrical muscle controller |
US8260416B2 (en) | 1996-01-08 | 2012-09-04 | Impulse Dynamics, N.V. | Electrical muscle controller |
US8301247B2 (en) | 1996-01-08 | 2012-10-30 | Impulse Dynamics, N.V. | Electrical muscle controller |
US8306617B2 (en) | 1996-01-08 | 2012-11-06 | Impulse Dynamics N.V. | Electrical muscle controller |
US9713723B2 (en) | 1996-01-11 | 2017-07-25 | Impulse Dynamics Nv | Signal delivery through the right ventricular septum |
US7221978B2 (en) | 1997-07-16 | 2007-05-22 | Metacure Nv | Smooth muscle controller |
US7120497B2 (en) | 1997-07-16 | 2006-10-10 | Metacure Nv | Smooth muscle controller |
US7966071B2 (en) | 1997-07-16 | 2011-06-21 | Metacure Limited | Method and apparatus for regulating glucose level |
US9265930B2 (en) | 1997-07-16 | 2016-02-23 | Metacure Limited | Methods and devices for modifying vascular parameters |
US8805507B2 (en) | 1997-07-16 | 2014-08-12 | Metacure Limited | Methods for controlling labor and treating menstrual cramps in uterine muscle |
US8219201B2 (en) | 1997-07-16 | 2012-07-10 | Metacure Limited | Smooth muscle controller for controlling the level of a chemical in the blood stream |
US7006871B1 (en) | 1997-07-16 | 2006-02-28 | Metacure N.V. | Blood glucose level control |
US8019421B2 (en) | 1999-03-05 | 2011-09-13 | Metacure Limited | Blood glucose level control |
US8346363B2 (en) | 1999-03-05 | 2013-01-01 | Metacure Limited | Blood glucose level control |
US8666495B2 (en) | 1999-03-05 | 2014-03-04 | Metacure Limited | Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar |
US9101765B2 (en) | 1999-03-05 | 2015-08-11 | Metacure Limited | Non-immediate effects of therapy |
US8700161B2 (en) | 1999-03-05 | 2014-04-15 | Metacure Limited | Blood glucose level control |
US11439815B2 (en) | 2003-03-10 | 2022-09-13 | Impulse Dynamics Nv | Protein activity modification |
US9931503B2 (en) | 2003-03-10 | 2018-04-03 | Impulse Dynamics Nv | Protein activity modification |
US7840262B2 (en) | 2003-03-10 | 2010-11-23 | Impulse Dynamics Nv | Apparatus and method for delivering electrical signals to modify gene expression in cardiac tissue |
US8326416B2 (en) | 2003-03-10 | 2012-12-04 | Impulse Dynamics Nv | Apparatus and method for delivering electrical signals to modify gene expression in cardiac tissue |
US8792985B2 (en) | 2003-07-21 | 2014-07-29 | Metacure Limited | Gastrointestinal methods and apparatus for use in treating disorders and controlling blood sugar |
US8548583B2 (en) | 2004-03-10 | 2013-10-01 | Impulse Dynamics Nv | Protein activity modification |
US8977353B2 (en) | 2004-03-10 | 2015-03-10 | Impulse Dynamics Nv | Protein activity modification |
US9440080B2 (en) | 2004-03-10 | 2016-09-13 | Impulse Dynamics Nv | Protein activity modification |
US11779768B2 (en) | 2004-03-10 | 2023-10-10 | Impulse Dynamics Nv | Protein activity modification |
US10352948B2 (en) | 2004-03-10 | 2019-07-16 | Impulse Dynamics Nv | Protein activity modification |
US8352031B2 (en) | 2004-03-10 | 2013-01-08 | Impulse Dynamics Nv | Protein activity modification |
US8244371B2 (en) | 2005-03-18 | 2012-08-14 | Metacure Limited | Pancreas lead |
US8934975B2 (en) | 2010-02-01 | 2015-01-13 | Metacure Limited | Gastrointestinal electrical therapy |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2014844C1 (en) | Method for treating viral diarrhea | |
MXPA04001605A (en) | Single dose azithromycin for treating respiratory infections. | |
Dubowitz et al. | Acute dermatomyositis presenting with pulmonary manifestations | |
JPS61103827A (en) | Novel immunoregulator and preparation | |
JPS6360932A (en) | Use of specific immunoregulatory agent for treating virus causing immune failure | |
Bischop et al. | Effects of rumen stasis on sulfamethazine blood levels after oral administration in sheep. | |
RU2150955C1 (en) | Method of treatment of children with infectious mononucleosis | |
US4871759A (en) | Method of treatment of mesenteric adenitis | |
RU2145872C1 (en) | Method of pertussis treatment in children | |
RU2170587C1 (en) | Method of treatment of children with acute respiratory viral infections | |
RU2180532C2 (en) | Method for treating the cases of papillomatosis | |
RU2020957C1 (en) | Method of treating persisting respiratory virus diseases | |
RU2097062C1 (en) | Method of treatment of an acute stenosed laryngotracheitis in children | |
RU2077335C1 (en) | Method to treat acute purulent destructive pneumonia in children | |
RU2104030C1 (en) | Method of viral diarrhea treatment | |
SU1754113A1 (en) | Method for treatment of acute enteric infections in children | |
RU2144375C1 (en) | Method of treatment of children with stenosing laryngotracheitis | |
SU1734756A1 (en) | Method for treating acute viral hepatitis | |
SU1731226A1 (en) | Method for treatment chlamidic infection of premature infants | |
SU1377113A1 (en) | Method of treatment of acute pneumonia of children at an early age | |
SU1068124A1 (en) | Method of rehabilitation of children,who suffered pneumonia | |
SU1252333A1 (en) | Method of treating intestine disbacterosis | |
SU1680200A1 (en) | Method for curing the cases of acute virus hepatitis | |
UA136881U (en) | METHOD OF PREVENTION OF BACTERIAL COMPLICATIONS IN PATIENTS WITH chickenpox | |
RU2195315C2 (en) | Method of treatment of children of first year life with acute respiratory viral disease |